Organic Chemistry TRIZ Cases

A mesogen epoxy with aliphatic chains improves heat conduction while lowering melting point and viscosity for solvent-free semiconductor packaging.

Continuous flow and controlled Grignard acylation raise yield and selectivity for 2-chlorothiazolyl ethanone while cutting effluent load.

Substituted pyridine compounds selectively block pan-KDM4 activity to suppress cancer stem-cell growth and EGFR-driven tumor progression.

Novel pyrazolopyridine compounds inhibit HPK1 to strengthen antitumor immunity and support treatment of autoimmune disease.

Partially unsaturated tocoflexol tails improve αTTP receptor binding, boosting bloodstream uptake and bioactivity beyond tocotrienols.

A fluorinated onium salt resin composition boosts photolithography sensitivity while improving LWR and CDU for fine resist pattern formation.

Glutamine derivatives replace toxic metal and antibacterial feed additives while improving animal growth and feed conversion.

Novel Formula (I) compounds retain Bcl-2 inhibition against the G101V mutation, improving potency for cancers and autoimmune disease.

Residual catalyst amines are cut to ≤20 ppm through heat, vacuum, and phosphate treatment to keep polyisocyanate chromaticity stable in storage.

Novel tetrahydropyridopyrimidine analogs inhibit YAP/TAZ-TEAD while balancing potency, toxicity, and pharmacokinetic properties for cancer and fibrosis treatment.

Alkyl lactone-derived hydroxyamides and hydroxyesters protect oilfield metal surfaces while reducing toxicity and improving biodegradability.

Moisture-activated aldimines enable polyurethane crosslinking without direct CO2 release, helping adhesives and sealants cure without bubbles.

By targeting influenza RNA endonuclease instead of neuraminidase, fused ring derivatives offer a route to address resistant influenza A strains.

Water-soluble benzophenone crosslinkers enable VOC-free UV-curable lubricious coatings for medical devices without harming plastic substrates.

Novel imidazole compounds modulate ER stress pathways to rescue cells from stress-induced death and reduce side effects in autoimmune treatment.

Novel pyridazines improve autotaxin inhibition in human whole blood and sustain LPA reduction for ATX-LPA mediated disorders.

Specific pyrazolo[1,5-a]pyridine substitutions improve RET kinase selectivity while preserving inhibition activity for RET-related cancers.

Selective DGKα and DGKζ inhibition restores T cell activation and may overcome resistance to PD(L)-1 and CTLA4 cancer immunotherapies.

A two-step oxidation route controls oxygen concentration and O2-to-5-methylfurfural ratio to raise FDCA yield while limiting off-gas risk.

Novel small molecules selectively activate PDE4 long forms to lower excessive cAMP signaling and expand therapeutic options.

Formula I compounds target CDK4 while limiting CDK6 and CDK1 inhibition, aiming to reduce neutropenia and improve cancer therapy.

Specific alkyl-substituted organic compounds form low-index, high-GSP films that improve OLED emission efficiency and lower driving voltage.

Strong charge-transfer heterocyclic compounds separate HOMO and LUMO to lower OLED driving voltage while improving emission efficiency and lifetime.

A base-initiated cyclization route replaces stepwise chromatography to improve yield, purity, and scalable isolation of bicyclic glycine-proline compounds.

Stabilized tryptophan synthase β-subunits improve thermostability, catalytic efficiency, and yields for producing non-canonical amino acids.

A protected hydroxy and pentafluorosulfanyl onium salt improves resist solubility, suppresses acid diffusion, and reduces pattern collapse.

Selective pyridine carboxamides target Nav1.8 to improve pain relief while balancing channel selectivity and pharmacokinetic limits.

Amine and tetradecanoic acid modification makes graphene water-soluble, cutting carbon steel corrosion and iron sulfide deposition at lower doses.

Covalent cysteine binding turns quinazoline TKIs into irreversible inhibitors that help overcome resistance and suppress tumor cell proliferation.

Structural THRβ selectivity helps lower cholesterol and blood fat while minimizing thyroid axis inhibition and related side effects.

Formula I compounds tune bicyclic nitrogen heterocycles to improve SIK2 inhibition and support therapy for cancers and other SIK-driven disorders.

Selective fused tricyclic absorbers block UV and 400-450 nm HEV light while preserving vision and fitting standard ophthalmic polymerization.

An amine-based OLED material improves carrier recombination, luminance, response speed, and resistance to Joule heating and high temperatures.

Covalently attaching electrochromic dyes to a polymer matrix limits diffusion and improves cycling durability, solar stability, and neutral color control.

Quindoline small molecules stabilize G-quadruplexes to suppress c-Myc and AR activity, addressing drug resistance in prostate cancer.

Novel CD73-modulating compounds inhibit AMP-to-adenosine signaling to counter tumor immunosuppression and strengthen anti-tumor immune responses.

Novel tetrahydroisoquinoline derivatives improve metabolic stability and potency, enabling lower-dose single-dose malaria treatment.

ATP-dependent Polθ helicase inhibition disrupts backup DNA repair, enabling treatment of HR-deficient cancers including PARP-resistant disease.

A basic substance keeps pH at 8 or higher to prevent quinoline degradation and surface gelation, preserving dissolution after storage.

3-oxabicyclo[3.3.1]nonene derivatives target ERα/β while avoiding GPER/GPR30 binding, reducing off-target estrogenic effects.

Amine oxide and acid diffusion control improve dry-state adhesion of thick resist films while maintaining sensitivity for reliable patterning.

Novel tricyclic MAT2A inhibitors improve selectivity in MTAP-deficient tumors by lowering SAM, suppressing PRMT5, and inducing apoptosis.

Selective NNMT inhibitors target cancer-associated fibroblasts to reverse the CAF phenotype, reduce tumor burden, and limit normal tissue toxicity.

Selective BRM and BRG1 inhibitor compounds modulate the BAF complex to treat cancer and viral disorders while limiting off-target toxicity.

Optimized OLED organic-layer compounds reduce side reactions and speed energy transfer to improve luminous efficiency and extend lifespan.

Bicyclic heteroaryl TYK2 inhibitors improve selectivity over JAK1/2/3, aiming to preserve efficacy while limiting side effects.

A latent carbamate salt catalyst enables Michael addition coatings to keep long potlife while curing quickly with strong adhesion and corrosion resistance.

Polar hydroxyl and amino substitutions enable small molecule NLRP3 inhibitors to control inflammasome activity with improved solubility and safety.

Novel aromatic TRIM21 ligands enable PROTAC recruitment and selective degradation of pathogenic proteins linked to cancer and neurodegeneration.

A liquid-solid circulating fluidized bed boosts heat and mass transfer to raise peroxide conversion, shorten reaction time, and improve epichlorohydrin selectivity.